Please enable JavaScript to continue using this application.

Compare $CADL vs $CRBP | Chartloom

Compare

$CADL vs $CRBP

Candel Therapeutics Inc · Corbus Pharmaceuticals Holdings Inc

CADL

Candel Therapeutics Inc

CRBP

Corbus Pharmaceuticals Holdings Inc

Compare $CADL vs $CRBP

Comparing Candel Therapeutics Inc and Corbus Pharmaceuticals Holdings Inc

CADLCandel Therapeutics Inc

CRBPCorbus Pharmaceuticals Holdings Inc

CADLCandel Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

82.7%

52W performance

57.8%

FCF yield

-7.9%

CRBPCorbus Pharmaceuticals Holdings Inc

Market cap

$100M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-31.6%

52W performance

-59.9%

FCF yield

-87.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CADL

CRBP

Detailed metrics comparison

CADL

Candel Therapeutics Inc

CRBP

Corbus Pharmaceuticals Holdings Inc

Market Cap

CADL$728M

CRBP$100M

Enterprise Value

CADL$575M

CRBP$76M

Price

CADL$9.94

CRBP$5.38

P/E Ratio

CADLN/A

CRBPN/A

P/S Ratio

CADL6,281.93x

CRBP76.49x

EV/Sales

CADL5,042.14x

CRBP61.41x

EV/EBITDA

CADL0.00x

CRBP0.00x

P/B Ratio

CADL6.18x

CRBP1.16x

P/FCF Ratio

CADLN/A

CRBPN/A

EV/FCF

CADL-10.02x

CRBP-0.88x

PEG Ratio

CADLN/A

CRBPN/A

Forward P/E (NTM)

CADLN/A

CRBPN/A

Forward P/S (NTM)

CADLN/A

CRBPN/A

Revenue (TTM)

CADL$0

CRBP$0

Revenue Growth (YoY)

CADLN/A

CRBPN/A

Forward Rev Growth

CADL371.1%

CRBP116.0%

Gross Margin (TTM)

CADL0.0%

CRBP0.0%

Operating Margin (TTM)

CADL0.0%

CRBP0.0%

EBITDA Margin (TTM)

CADL0.0%

CRBP0.0%

Net Margin (TTM)

CADL0.0%

CRBP0.0%

FCF Margin (TTM)

CADLN/A

CRBPN/A

Net Income (TTM)

CADL$-89M

CRBP$-102M

FCF (TTM)

CADL$-57M

CRBP$-87M

EPS (TTM)

CADL-$1.19

CRBP-$5.25

ROE (TTM)

CADL-8938.0%

CRBP-8705.0%

ROA (TTM)

CADL-5631.0%

CRBP-7422.0%

ROIC (TTM)

CADL-6512.0%

CRBP-8705.0%

Cash

CADL$202M

CRBP$23M

Debt

CADL$48M

CRBP$0

Net Cash/Debt

CADL$154M

CRBP$23M

Current Ratio (TTM)

CADL16.09x

CRBP5.71x

Quick Ratio (TTM)

CADL15.89x

CRBP5.62x

Debt/Equity (TTM)

CADL0.38x

CRBP0.00x

Debt/Assets (TTM)

CADL0.0%

CRBP0.0%

Interest Coverage (TTM)

CADLN/A

CRBPN/A

Net Debt/EBITDA (TTM)

CADL0.00x

CRBP0.00x

Beta

CADL-0.28

CRBP2.74

52W Performance

CADL57.8%

CRBP-59.9%

YTD Performance

CADL82.7%

CRBP-31.6%

% from 52W High

CADL-29.0%

CRBP-73.8%

% from 52W Low

CADL128.5%

CRBP4.9%

Asset Turnover (TTM)

CADL0.00x

CRBP0.01x

FCF Yield (TTM)

CADL-7.9%

CRBP-87.0%

Earnings Yield (TTM)

CADL-12.2%

CRBP-102.2%

Dividend Yield (TTM)

CADLN/A

CRBPN/A

Rule of 40

CADL0.0

CRBP0.0

EV/GP/RG

CADLN/A

CRBPN/A

Ticker research

View CADL research View CRBP research

Metric	CADL Candel Therapeutics Inc	CRBP Corbus Pharmaceuticals Holdings Inc
Market & Valuation
Market Cap	$728M	$100M
Enterprise Value	$575M	$76M
Price	$9.94	$5.38
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	76.49x
EV/Sales	5,042.14x	61.41x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	1.16x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-0.88x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	371.1%	116.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-89M	$-102M
FCF (TTM)	$-57M	$-87M
EPS (TTM)	-$1.19	-$5.25
ROE (TTM)	-8938.0%	-8705.0%
ROA (TTM)	-5631.0%	-7422.0%
ROIC (TTM)	-6512.0%	-8705.0%
Financial Health
Cash	$202M	$23M
Debt	$48M	$0
Net Cash/Debt	$154M	$23M
Current Ratio (TTM)	16.09x	5.71x
Quick Ratio (TTM)	15.89x	5.62x
Debt/Equity (TTM)	0.38x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.74
52W Performance	57.8%	-59.9%
YTD Performance	82.7%	-31.6%
% from 52W High	-29.0%	-73.8%
% from 52W Low	128.5%	4.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-7.9%	-87.0%
Earnings Yield (TTM)	-12.2%	-102.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CADL research	View CRBP research

Valuation

P/S Ratio

CRBP

76.49x

CADL

6,281.93x

EV/FCF

CADL

-10.02x

CRBP

-0.88x

Growth & revenue

Forward Revenue Growth

CADL

371.1%

CRBP

116.0%

Profitability & performance

Gross Margin

CADL

0.0%

CRBP

0.0%

ROE

CRBP

-8705.0%

CADL

-8938.0%

FCF Yield %

CADL

-7.9%

CRBP

-87.0%

52-Week Performance

CADL

57.8%

CRBP

-59.9%

Detailed metrics comparison

CADL

Candel Therapeutics Inc

CRBP

Corbus Pharmaceuticals Holdings Inc

Market Cap

CADL$728M

CRBP$100M

Enterprise Value

CADL$575M

CRBP$76M

Price

CADL$9.94

CRBP$5.38

P/E Ratio

CADLN/A

CRBPN/A

P/S Ratio

CADL6,281.93x

CRBP76.49x

EV/Sales

CADL5,042.14x

CRBP61.41x

EV/EBITDA

CADL0.00x

CRBP0.00x

P/B Ratio

CADL6.18x

CRBP1.16x

P/FCF Ratio

CADLN/A

CRBPN/A

EV/FCF

CADL-10.02x

CRBP-0.88x

PEG Ratio

CADLN/A

CRBPN/A

Forward P/E (NTM)

CADLN/A

CRBPN/A

Forward P/S (NTM)

CADLN/A

CRBPN/A

Revenue (TTM)

CADL$0

CRBP$0

Revenue Growth (YoY)

CADLN/A

CRBPN/A

Forward Rev Growth

CADL371.1%

CRBP116.0%

Gross Margin (TTM)

CADL0.0%

CRBP0.0%

Operating Margin (TTM)

CADL0.0%

CRBP0.0%

EBITDA Margin (TTM)

CADL0.0%

CRBP0.0%

Net Margin (TTM)

CADL0.0%

CRBP0.0%

FCF Margin (TTM)

CADLN/A

CRBPN/A

Net Income (TTM)

CADL$-89M

CRBP$-102M

FCF (TTM)

CADL$-57M

CRBP$-87M

EPS (TTM)

CADL-$1.19

CRBP-$5.25

ROE (TTM)

CADL-8938.0%

CRBP-8705.0%

ROA (TTM)

CADL-5631.0%

CRBP-7422.0%

ROIC (TTM)

CADL-6512.0%

CRBP-8705.0%

Cash

CADL$202M

CRBP$23M

Debt

CADL$48M

CRBP$0

Net Cash/Debt

CADL$154M

CRBP$23M

Current Ratio (TTM)

CADL16.09x

CRBP5.71x

Quick Ratio (TTM)

CADL15.89x

CRBP5.62x

Debt/Equity (TTM)

CADL0.38x

CRBP0.00x

Debt/Assets (TTM)

CADL0.0%

CRBP0.0%

Interest Coverage (TTM)

CADLN/A

CRBPN/A

Net Debt/EBITDA (TTM)

CADL0.00x

CRBP0.00x

Beta

CADL-0.28

CRBP2.74

52W Performance

CADL57.8%

CRBP-59.9%

YTD Performance

CADL82.7%

CRBP-31.6%

% from 52W High

CADL-29.0%

CRBP-73.8%

% from 52W Low

CADL128.5%

CRBP4.9%

Asset Turnover (TTM)

CADL0.00x

CRBP0.01x

FCF Yield (TTM)

CADL-7.9%

CRBP-87.0%

Earnings Yield (TTM)

CADL-12.2%

CRBP-102.2%

Dividend Yield (TTM)

CADLN/A

CRBPN/A

Rule of 40

CADL0.0

CRBP0.0

EV/GP/RG

CADLN/A

CRBPN/A

Ticker research

View CADL research View CRBP research

Metric	CADL Candel Therapeutics Inc	CRBP Corbus Pharmaceuticals Holdings Inc
Market & Valuation
Market Cap	$728M	$100M
Enterprise Value	$575M	$76M
Price	$9.94	$5.38
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	76.49x
EV/Sales	5,042.14x	61.41x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	1.16x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-0.88x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	371.1%	116.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-89M	$-102M
FCF (TTM)	$-57M	$-87M
EPS (TTM)	-$1.19	-$5.25
ROE (TTM)	-8938.0%	-8705.0%
ROA (TTM)	-5631.0%	-7422.0%
ROIC (TTM)	-6512.0%	-8705.0%
Financial Health
Cash	$202M	$23M
Debt	$48M	$0
Net Cash/Debt	$154M	$23M
Current Ratio (TTM)	16.09x	5.71x
Quick Ratio (TTM)	15.89x	5.62x
Debt/Equity (TTM)	0.38x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.74
52W Performance	57.8%	-59.9%
YTD Performance	82.7%	-31.6%
% from 52W High	-29.0%	-73.8%
% from 52W Low	128.5%	4.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-7.9%	-87.0%
Earnings Yield (TTM)	-12.2%	-102.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CADL research	View CRBP research